Fresenius brings mAbxience fully into its Biopharma business with acquisition of remaining 45% stake

(PRESS RELEASE) BAD HOMBURG, Germany, 2-Oct-2026 — /EuropaWire/ — Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% of mAbxience Holding S.L. from Insud Pharma S.L. and Invim Corporativo, S.L. for total consideration of up to €750 million, including a contingent payment of €50 million upon site-approvals. The transaction was signed and completed on 30 September 2026, and no regulatory approvals were required.

Fresenius acquired a 55% majority stake in mAbxience in August 2022 and has controlled and consolidated the business since then. The latest transaction completes that ownership structure, with the biosimilars platform now wholly owned within Fresenius Kabi’s Biopharma business and covering the value chain from research through commercialization.

The move builds on a partnership that Fresenius says has delivered development, manufacturing, technology-transfer and regulatory milestones. Full ownership gives the company the entire economic benefit of the platform and additional flexibility to invest in manufacturing capacity, select future biosimilar opportunities and pursue licensing partnerships as a large wave of biologics loses exclusivity.

Fresenius expects the biosimilars market referenced in the release to grow approximately six times by 2035 to more than €180 billion. The company said bringing the organizations together under full ownership creates a stronger platform for quality, supply resilience and operational freedom while supporting future innovation and broader patient access to high-quality biosimilars. The transaction is also consistent with the capital allocation priorities under #FutureFresenius.

Michael Sen, Chief Executive Officer of Fresenius, said: “Completing the acquisition of mAbxience marks the next milestone in building a leading, vertically integrated biopharma business at scale. When we first invested in mAbxience four years ago, the market opportunity was promising but still evolving. Our initial majority stake gave us access to a highly competitive platform while managing risk. Since then, the market has developed strongly, mAbxience has delivered, and Fresenius now has the financial strength to take this next step. Full ownership gives us complete control over cost, capacity and launch timing, and full economic benefit, as the next wave of biologics loses exclusivity. For patients, that means dependable access to high-quality biosimilars; for shareholders, it is a disciplined investment in a business we know well.”

Jurgen Van Broeck, Chief Executive Officer of mAbxience, said: “mAbxience was founded to serve patients, while proving that world-class biologics could be developed and manufactured at a cost the world could afford. Since 2022, our partnership with Fresenius has demonstrated the strength of combining our people, expertise, and capabilities. I would also like to recognize and thank Insud Pharma for its support and commitment over the past decade. The success of mAbxience today is built on the vision, dedication and hard work of many people who have contributed to this journey from the very beginning. Full ownership is the natural next step and creates an even stronger platform for innovation, growth, and long-term impact for patients, customers, and partners. As we begin this next chapter together, we will continue to build on the entrepreneurial spirit, scientific expertise, and commitment to patients that have driven mAbxience’s success.”

mAbxience operates three multi-product drug substance facilities in Spain and Latin America and employs more than 1,300 people. The company develops and manufactures biosimilar monoclonal antibodies and provides contract development and manufacturing services to partners. In 2025, mAbxience generated more than €320 million in revenue and contributed an earnings before interest, taxes, depreciation and amortization (EBITDA) margin that was accretive to the overall Fresenius Kabi margin.

The mAbxience portfolio includes four products on the market and eight candidates in development. Together with Fresenius Kabi’s development, regulatory and commercial capabilities, the platform spans the full value chain from laboratory to patient.

Jurgen Van Broeck, Chief Executive Officer of mAbxience, will continue to lead the business and will report to Dr. Sang-Jin Pak, President Biopharma at Fresenius. Fresenius said full ownership positions the platform for further scale, including pipeline expansion opportunities, within the Group’s unchanged financial framework.

Financial Considerations

• Consideration: Up to €750 million in cash, including a contingent payment of €50 million upon site-approvals.
• Funding: Available liquidity and operating cash flow. No new financing was required.
• Balance sheet: The consideration settles the put option liability over the 45% non-controlling interest recognized in the Group’s consolidated balance sheet. Following the transaction, net debt to EBITDA is expected to increase by approximately 20 basis points, while leverage for the full year is expected to be towards the lower end of the self-imposed target corridor of 2.5x to 3.0x.
• Accounting: Under International Financial Reporting Standards, the acquisition of a non-controlling interest is an equity transaction; no goodwill arises. A 45% non-controlling interest has been presented to date: The transaction is expected to be immediately accretive to Group core earnings per share.
• Returns: The investment is expected to further improve the return on invested capital (ROIC) already above Fresenius’ cost of capital after the integration, in line with the Group’s capital allocation criteria.
• Credit ratings: Fresenius is rated BBB (outlook positive) by S&P, Baa3 (outlook stable) by Moody’s and BBB- (outlook positive) by Fitch. A strong balance sheet and continued deleveraging remain priorities.
• Guidance: No change to full-year 2026 guidance or to the 2030 Biopharma ambition of approximately doubling revenue compared with 2025 at an EBIT margin of around 20%.

Notes to Editors

The 31 March 2022 announcement of Fresenius Kabi’s acquisition of a 55% majority stake in mAbxience is available here, and the 1 August 2022 completion announcement here. The Biopharma ‘Meet the Management’ presentation of 15 December 2025 is available here.

About mAbxience

mAbxience is a Spanish-based company specializing in the development, production and commercialization of biopharmaceuticals. mAbxience is a wholly owned company of Fresenius SE & Co. KGaA and part of Fresenius Kabi’s Biopharma business.

With over fifteen years of expertise, mAbxience’s mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance quality of life by ensuring universal access to high-caliber medicines. With four approved products and a robust pipeline in development, mAbxience has established a B2B presence in over 100 markets. Alongside this, the company has formed a network with more than 40 partners and built a dedicated team of over 1,300 professionals. Its three multiproduct facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization (CDMO) services, utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions.

For more information, visit http://www.mabxience.com or connect with mAbxience on LinkedIn.

About Fresenius

Fresenius (XETR: FRE; OTCM: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit http://www.fresenius.com and follow Fresenius on LinkedIn.

Cautionary Statement on Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu
Chairman of the Supervisory Board: Wolfgang Kirsch

Media Contact

Steffi Kim
T: +49 (0) 175 32 84 722
steffi.kim@fresenius.com